Investment & Funding


NATA is funded by a £30M public investment from the UK Strategic Priorities Fund through MRC and UK Research and Innovation (UKRI). Our strategy is to develop a hub of world-leading excellence for the acceleration of NAT technologies. In addition, we fund two Research Challenge consortia to address critical issues in the manufacture and delivery of NATs. By tackling these challenges and others, we can unlock the full therapeutic potential of NATs to bring health benefits to patients.


NATA can partner to directly fund collaborations against our framework of strategic fit, high quality science and translational end points. We look to provide funding to a diverse set of charities, academic institutions and SMEs.